Kodiak Sciences Inc (KOD) - Net Assets
Based on the latest financial reports, Kodiak Sciences Inc (KOD) has net assets worth $157.38 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($351.53 Million) and total liabilities ($194.15 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Kodiak Sciences Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $157.38 Million |
| % of Total Assets | 44.77% |
| Annual Growth Rate | N/A |
| 5-Year Change | -76.27% |
| 10-Year Change | N/A |
| Growth Volatility | 120.8 |
Kodiak Sciences Inc - Net Assets Trend (2016–2025)
This chart illustrates how Kodiak Sciences Inc's net assets have evolved over time, based on quarterly financial data. Also explore Kodiak Sciences Inc (KOD) total assets for the complete picture of this company's asset base.
Annual Net Assets for Kodiak Sciences Inc (2016–2025)
The table below shows the annual net assets of Kodiak Sciences Inc from 2016 to 2025. For live valuation and market cap data, see Kodiak Sciences Inc (KOD) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $157.38 Million | +4.72% |
| 2024-12-31 | $150.29 Million | -43.45% |
| 2023-12-31 | $265.78 Million | -39.06% |
| 2022-12-31 | $436.17 Million | -34.24% |
| 2021-12-31 | $663.32 Million | -22.94% |
| 2020-12-31 | $860.75 Million | +149.23% |
| 2019-12-31 | $345.36 Million | +297.73% |
| 2018-12-31 | $86.83 Million | +226.32% |
| 2017-12-31 | $-68.74 Million | -67.31% |
| 2016-12-31 | $-41.08 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kodiak Sciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 151731800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | 0.00% |
| Other Components | $1.72 Billion | 1090.39% |
| Total Equity | $157.38 Million | 100.00% |
Kodiak Sciences Inc Competitors by Market Cap
The table below lists competitors of Kodiak Sciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Power Integrations Inc
NASDAQ:POWI
|
$2.62 Billion |
|
Lojas Renner S.A.
SA:LREN3
|
$2.62 Billion |
|
Ermenegildo Zegna NV
NYSE:ZGN
|
$2.62 Billion |
|
Xinjiang Zhongtai Chemical Co Ltd
SHE:002092
|
$2.62 Billion |
|
AXT Inc
NASDAQ:AXTI
|
$2.62 Billion |
|
StubHub Holdings, Inc.
NYSE:STUB
|
$2.62 Billion |
|
Newmark Group Inc
NASDAQ:NMRK
|
$2.62 Billion |
|
FADU Inc.
KQ:440110
|
$2.62 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kodiak Sciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 150,288,000 to 157,383,000, a change of 7,095,000 (4.7%).
- Net loss of 229,967,000 reduced equity.
- New share issuances of 172,960,000 increased equity.
- Other factors increased equity by 64,102,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-229.97 Million | -146.12% |
| Share Issuances | $172.96 Million | +109.9% |
| Other Changes | $64.10 Million | +40.73% |
| Total Change | $- | 4.72% |
Book Value vs Market Value Analysis
This analysis compares Kodiak Sciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 14.86x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-5.52 | $43.96 | x |
| 2017-12-31 | $-2.59 | $43.96 | x |
| 2018-12-31 | $2.42 | $43.96 | x |
| 2019-12-31 | $9.12 | $43.96 | x |
| 2020-12-31 | $18.82 | $43.96 | x |
| 2021-12-31 | $12.81 | $43.96 | x |
| 2022-12-31 | $8.35 | $43.96 | x |
| 2023-12-31 | $5.07 | $43.96 | x |
| 2024-12-31 | $2.86 | $43.96 | x |
| 2025-12-31 | $2.96 | $43.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kodiak Sciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -146.12%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.23x
- Recent ROE (-146.12%) is below the historical average (-55.51%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.02 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-21.06 Million |
| 2018 | -47.73% | 0.00% | 0.00x | 1.06x | $-50.13 Million |
| 2019 | -13.71% | 0.00% | 0.00x | 1.04x | $-81.90 Million |
| 2020 | -15.46% | 0.00% | 0.00x | 1.24x | $-219.17 Million |
| 2021 | -40.25% | 0.00% | 0.00x | 1.36x | $-333.32 Million |
| 2022 | -76.54% | 0.00% | 0.00x | 1.53x | $-377.44 Million |
| 2023 | -98.01% | 0.00% | 0.00x | 1.80x | $-287.07 Million |
| 2024 | -117.25% | 0.00% | 0.00x | 2.23x | $-191.24 Million |
| 2025 | -146.12% | 0.00% | 0.00x | 2.23x | $-245.71 Million |
Industry Comparison
This section compares Kodiak Sciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kodiak Sciences Inc (KOD) | $157.38 Million | 0.00% | 1.23x | $2.62 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Kodiak Sciences Inc
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in… Read more